FBLG news

FibroBiologics digitally signed a securities purchase agreement with Peak One Opportunity Fund on Oct 7, 2026, to sell a $1M convertible debenture. This secondary offering of approximately 89% of the debt's face value is potentially dilutive.

FibroBiologics issued a warrant granting the holder the right to subscribe for shares until September 2026 after a Securities Purchase Agreement. This document details the terms, exercise price, and voting rights associated with the financial instrument.

FibroBiologics Inc. added legendary sports agent and health advocate Leigh Steinberg to its board of directors to support its fibroblast-based pipeline. This leadership appointment may signal a strategic shift toward leveraging the executive's resources to advance commercialization.

FibroBiologics appointed former NASA astronaut Dr. Kathleen Rubins to its board of directors. Her expertise in space medicine enhances the biotech firm's scientific pipeline for fibroblast-based therapies.

FibroBiologics filed a Pre-Funded Common Stock Purchase Warrant allowing investors to buy shares at a nominal price. This security structure allows the company to raise capital without triggering immediate dilution for existing public shareholders.

FibroBiologics filed a new 2026 Equity and Incentive Compensation Plan to establish rules for granting awards. The document defines key terms for stock options and cash incentives, supporting potential long-term employee retention.